Centene Valuation
Is CNC * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CNC * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CNC * (MX$1245) is trading below our estimate of fair value (MX$3112.84)
Significantly Below Fair Value: CNC * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CNC *?
Other financial metrics that can be useful for relative valuation.
What is CNC *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$41.51b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.3x |
Enterprise Value/EBITDA | 6.9x |
PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does CNC *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 44.8x | ||
HUM Humana | 20.3x | 14.2% | US$40.4b |
MOH Molina Healthcare | 19.4x | 16.1% | US$20.8b |
ELV Elevance Health | 20.1x | 12.3% | US$125.3b |
HQY HealthEquity | 119.6x | 41.4% | US$6.7b |
CNC * Centene | 15.2x | 9.1% | Mex$41.5b |
Price-To-Earnings vs Peers: CNC * is good value based on its Price-To-Earnings Ratio (15.2x) compared to the peer average (44.8x).
Price to Earnings Ratio vs Industry
How does CNC *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: CNC * is good value based on its Price-To-Earnings Ratio (15.2x) compared to the Global Healthcare industry average (22.5x).
Price to Earnings Ratio vs Fair Ratio
What is CNC *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 15.2x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CNC *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$1,506.02 0% | 9.7% | Mex$1,858.76 | Mex$1,284.23 | n/a | 16 |
May ’25 | Mex$1,245.00 | Mex$1,507.46 +21.1% | 10.1% | Mex$1,883.95 | Mex$1,255.39 | n/a | 17 |
Apr ’25 | n/a | Mex$1,489.63 0% | 10.3% | Mex$1,840.75 | Mex$1,226.61 | n/a | 17 |
Mar ’25 | Mex$1,321.35 | Mex$1,512.08 +14.4% | 10.0% | Mex$1,880.35 | Mex$1,253.00 | n/a | 16 |
Feb ’25 | Mex$1,287.96 | Mex$1,471.91 +14.3% | 10.0% | Mex$1,856.26 | Mex$1,236.94 | n/a | 17 |
Jan ’25 | n/a | Mex$1,464.03 0% | 9.7% | Mex$1,873.55 | Mex$1,248.47 | n/a | 16 |
Dec ’24 | Mex$1,270.70 | Mex$1,450.93 +14.2% | 10.8% | Mex$1,921.04 | Mex$1,257.41 | n/a | 16 |
Nov ’24 | n/a | Mex$1,498.61 0% | 10.8% | Mex$1,983.28 | Mex$1,298.15 | n/a | 16 |
Oct ’24 | n/a | Mex$1,396.63 0% | 10.9% | Mex$1,883.87 | Mex$1,215.95 | n/a | 18 |
Sep ’24 | Mex$1,041.07 | Mex$1,377.75 +32.3% | 10.3% | Mex$1,843.59 | Mex$1,189.95 | n/a | 19 |
Aug ’24 | n/a | Mex$1,397.80 0% | 10.1% | Mex$1,841.88 | Mex$1,188.85 | n/a | 19 |
Jul ’24 | n/a | Mex$1,443.15 0% | 10.0% | Mex$1,893.11 | Mex$1,221.92 | n/a | 20 |
Jun ’24 | n/a | Mex$1,513.32 0% | 9.2% | Mex$1,958.30 | Mex$1,263.99 | n/a | 19 |
May ’24 | Mex$1,200.00 | Mex$1,534.69 +27.9% | 10.0% | Mex$1,972.15 | Mex$1,272.93 | Mex$1,245.00 | 19 |
Apr ’24 | n/a | Mex$1,666.48 0% | 11.0% | Mex$2,048.31 | Mex$1,322.09 | n/a | 19 |
Mar ’24 | n/a | Mex$1,685.49 0% | 9.2% | Mex$2,012.82 | Mex$1,445.57 | Mex$1,321.35 | 18 |
Feb ’24 | Mex$1,426.00 | Mex$1,865.22 +30.8% | 7.6% | Mex$2,078.30 | Mex$1,605.96 | Mex$1,287.96 | 18 |
Jan ’24 | Mex$1,588.77 | Mex$1,936.25 +21.9% | 8.1% | Mex$2,226.69 | Mex$1,645.81 | n/a | 18 |
Dec ’23 | Mex$1,637.17 | Mex$1,997.19 +22.0% | 6.6% | Mex$2,267.79 | Mex$1,715.63 | Mex$1,270.70 | 18 |
Nov ’23 | Mex$1,657.14 | Mex$1,997.19 +20.5% | 6.6% | Mex$2,267.79 | Mex$1,715.63 | n/a | 18 |
Oct ’23 | Mex$1,566.00 | Mex$2,081.68 +32.9% | 6.9% | Mex$2,336.07 | Mex$1,772.19 | n/a | 19 |
Sep ’23 | Mex$1,832.77 | Mex$2,082.42 +13.6% | 6.9% | Mex$2,320.35 | Mex$1,760.26 | Mex$1,041.07 | 19 |
Aug ’23 | n/a | Mex$2,105.64 0% | 6.6% | Mex$2,363.37 | Mex$1,792.90 | n/a | 20 |
Jul ’23 | Mex$1,647.34 | Mex$1,921.85 +16.7% | 7.4% | Mex$2,163.26 | Mex$1,642.48 | n/a | 19 |
Jun ’23 | Mex$1,612.16 | Mex$1,896.66 +17.6% | 8.5% | Mex$2,215.34 | Mex$1,621.94 | n/a | 18 |
May ’23 | n/a | Mex$1,948.43 0% | 7.9% | Mex$2,285.07 | Mex$1,673.00 | Mex$1,200.00 | 18 |
Analyst Forecast: Target price is less than 20% higher than the current share price.